Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000563268
Ethics application status
Approved
Date submitted
9/07/2009
Date registered
9/07/2009
Date last updated
3/12/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Internet-based treatment of generalized anxiety disorder (the Worry program): A randomized controlled study exploring the role of a clinician.
Scientific title
A randomized controlled trial comparing clinician-assisted Internet based treatment for generalized anxiety disorder (GAD) vs. self-guided Internet-based treatment for GAD vs. a waitlist control condition on severity of symptoms of generalized anxiety disorder.
Secondary ID [1] 288062 0
Nil
Universal Trial Number (UTN)
Trial acronym
GAD RCT2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mental Health 237203 0
Condition category
Condition code
Mental Health 237522 237522 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will be randomly assigned to one of three groups: 1) Treatment with clinician-assisted Internet based treatment for GAD, or; 2) Treatment with self-guided Internet based treatment for GAD, or; 3) Waitlist control. All participants will meet Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) criteria for GAD. All group 1 and group 2 participants will complete 6 lessons of Internet based treatment about the management of symptoms of GAD. One lesson will be completed every 7 to 14 days. Each lesson will take about 15 minutes to complete. Group 1 participants will have access to summaries of each lesson, will contribute to an online forum moderated by a clinical psychologist or psychiatrist, and will receive weekly reminder emails. Group 2 participants will have access to summaries of each lesson, and will receive weekly reminder emails. The duration of the program is up to 10 weeks, but participants will be contacted 3 months post program and asked to complete follow-up questionnaires. Study questionnaires will be administered at application, pre-treatment, post-treatment, and at 3-month post-treatment. These will take about 20 minutes to complete. The treatment materials are based on cognitive behavioural techniques.
Intervention code [1] 236904 0
Treatment: Other
Comparator / control treatment
Waitlist control group. These participants remain on the waitlist until the treatment groups have completed their treatment (10 weeks). At that time (10 weeks) the waitlist group will receive the same treatment as Treatment Group 1.
Control group
Active

Outcomes
Primary outcome [1] 238332 0
Symptoms of GAD are measured by the Generalized Anxiety Disorder - 7 Item (GAD-7) questionnaire.
Timepoint [1] 238332 0
Administered at application, pre-treatment, post-treatment, and at 3-months post-treatment.
Primary outcome [2] 238333 0
Symptoms of GAD are also measured by the Penn State Worry Questionnaire (PSWQ).
Timepoint [2] 238333 0
Administered at pre-treatment, post-treatment, and at 3-months post-treatment.
Secondary outcome [1] 244738 0
Symptoms and severity of depression is measured by the Patient Health Questionnaire-9 (PHQ-9).
Timepoint [1] 244738 0
Administered at application, pre-treatment, post-treatment, and at 3-months post-treatment
Secondary outcome [2] 244739 0
Psychological distress is measured by the Kessler-10 (K-10).
Timepoint [2] 244739 0
Administered at application, pre-treatment, post-treatment, and at 3-months post-treatment
Secondary outcome [3] 244740 0
Disability is measured by the Sheehan Disability Scale.
Timepoint [3] 244740 0
Administered at application, pre-treatment, post-treatment, and at 3-months post-treatment

Eligibility
Key inclusion criteria
Meet Diagnostic and Statistical Manual of the American Psychiatric Association-4th Edition (DSM-IV) criteria for GAD - Internet access + printer access. - Australian citizen- Males and females
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Current substance abuse/dependence- Psychotic disorder- Current or planned psychological treatment during study duration- Change in medications during last 1 month or intended change during study duration

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants apply on line, followed by a telephone interview to confirm diagnosis via the Mini-International Neuropsychiatric Interview (MINI 5.0.0), a structured diagnostic interview. Participants will be randomized using a list generated prior to the study. Allocation concealment will occur by contacting the holder of the allocation schedule who is off-site.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A randomisation list will be generated prior to the study using computer software.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
7/09/2009
Actual
7/09/2009
Date of last participant enrolment
Anticipated
Actual
1/12/2009
Date of last data collection
Anticipated
Actual
Sample size
Target
120
Accrual to date
Final
150
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 237301 0
University
Name [1] 237301 0
School of Psychiatry, University of New South Wales at St Vincent's Hospital
Country [1] 237301 0
Australia
Primary sponsor type
University
Name
School of Psychiatry, University of New South Wales at St Vincent's Hospital
Address
299 Forbes Street Darlinghurst NSW2010
Country
Australia
Secondary sponsor category [1] 236785 0
None
Name [1] 236785 0
Address [1] 236785 0
Country [1] 236785 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 239398 0
Ethics committee address [1] 239398 0
Ethics committee country [1] 239398 0
Date submitted for ethics approval [1] 239398 0
16/06/2009
Approval date [1] 239398 0
01/09/2009
Ethics approval number [1] 239398 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 29874 0
Prof Nick Titov
Address 29874 0
Department of Psychology
Macquarie University
NSW 2109
Country 29874 0
Australia
Phone 29874 0
61 2 9850 9979
Fax 29874 0
Email 29874 0
[email protected]
Contact person for public queries
Name 13121 0
Dr Nickolai Titov
Address 13121 0
299 Forbes Street
Darlinghurst
NSW2010
Country 13121 0
Australia
Phone 13121 0
612 8382 1726
Fax 13121 0
612 8382 1721
Email 13121 0
[email protected]
Contact person for scientific queries
Name 4049 0
Dr Nickolai Titov
Address 4049 0
299 Forbes Street
Darlinghurst
NSW2010
Country 4049 0
Australia
Phone 4049 0
612 8382 1726
Fax 4049 0
612 8382 1721
Email 4049 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.